OBI Pharma is developing novel therapeutic agents
for unmet medical needs.
Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
Title: OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab Abstract number: 5946 / Poster number: 5946/7 Title: Globo H-targeted CAR T cell cancer immunotherapy Abstract number: 4084 / Poster Number: 4084/3
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
Poster Presentations to highlight the latest research on OBI-999’s (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and OBI’s development of CAR T-cell cancer immunotherapy targeting Globo H. OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab (anti-PD1 mAb) in …
OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs
OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced discontinuation of the Phase 1/2 Study* for OBI 888, a Globo H antibody, upon completion of enrollment in our investigative sites. “We are pleased that the preliminary data from our Phase 1/2 study demonstrated that OBI 888 is a safe …